FDA Clears HeartLung's AI-CVD®, Enabling the Broadest Opportunistic Cardiovascular & Multisystem CT Screening Platform

FDA-cleared AI-CVD® extracts preventive insights from routine CT—identifying hidden cardiovascular, metabolic, and skeletal risk in ~40M scans/year HOUSTON, Jan. 16, 2026 /PRNewswire-PRWeb/ -- HeartLung Corporation today announced U.S. Food and Drug Administration (FDA) clearance of...